Artificial Intelligence-assisted Diagnosis and Prognostication in Low Ejection Fraction Using Electrocardiograms
Primary Purpose
Left Ventricular Systolic Dysfunction (Disorder)
Status
Recruiting
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
AI-enabled ECG-based Screening Tool
Sponsored by
About this trial
This is an interventional screening trial for Left Ventricular Systolic Dysfunction (Disorder)
Eligibility Criteria
Inclusion Criteria:
- Patients with EF>50% or without Transesophageal Echocardiography (TEE)
Exclusion Criteria:
- Patients with a history of heart failure or an EF<= 35%.
Sites / Locations
- National Defense Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Intervention
Control
Arm Description
Patients randomized to intervention will have access to the screening tool.
Patients randomized to control will continue routine practice.
Outcomes
Primary Outcome Measures
New Diagnosis of Low Ejection Fraction(defined as ejection fraction ≤35%)
Ejection fraction obtained by echocardiography
Secondary Outcome Measures
All cause mortality(death)
After performing an electrocardiogram, the patient's survival is tracked.
Cardiovascular cause mortality(death)
After performing an electrocardiogram, the patient's survival is tracked.
Transesophageal Echocardiography (TEE)
After performing the ECG examination, perform theTransesophageal Echocardiography examination
Full Information
NCT ID
NCT05117970
First Posted
November 1, 2021
Last Updated
February 3, 2023
Sponsor
National Defense Medical Center, Taiwan
1. Study Identification
Unique Protocol Identification Number
NCT05117970
Brief Title
Artificial Intelligence-assisted Diagnosis and Prognostication in Low Ejection Fraction Using Electrocardiograms
Official Title
Artificial Intelligence-assisted Diagnosis and Prognostication in Low Ejection Fraction Using Electrocardiograms
Study Type
Interventional
2. Study Status
Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 9, 2021 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
National Defense Medical Center, Taiwan
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a randomized controlled trial (RCT) to test a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of left ventricular systolic dysfunction.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Left Ventricular Systolic Dysfunction (Disorder)
7. Study Design
Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
84000 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Intervention
Arm Type
Experimental
Arm Description
Patients randomized to intervention will have access to the screening tool.
Arm Title
Control
Arm Type
No Intervention
Arm Description
Patients randomized to control will continue routine practice.
Intervention Type
Other
Intervention Name(s)
AI-enabled ECG-based Screening Tool
Intervention Description
Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative.The system will send a message to corresponding physicians if positive finding.
Primary Outcome Measure Information:
Title
New Diagnosis of Low Ejection Fraction(defined as ejection fraction ≤35%)
Description
Ejection fraction obtained by echocardiography
Time Frame
Within 90 days
Secondary Outcome Measure Information:
Title
All cause mortality(death)
Description
After performing an electrocardiogram, the patient's survival is tracked.
Time Frame
Within 365 days
Title
Cardiovascular cause mortality(death)
Description
After performing an electrocardiogram, the patient's survival is tracked.
Time Frame
Within 365 days
Title
Transesophageal Echocardiography (TEE)
Description
After performing the ECG examination, perform theTransesophageal Echocardiography examination
Time Frame
Within 90 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with EF>50% or without Transesophageal Echocardiography (TEE)
Exclusion Criteria:
Patients with a history of heart failure or an EF<= 35%.
Facility Information:
Facility Name
National Defense Medical Center
City
Taipei
ZIP/Postal Code
114
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tai-Lung Cha
Phone
+886287923100
Email
director@mail.ndmctsgh.edu.tw
First Name & Middle Initial & Last Name & Degree
Ching-Liang Ho
Phone
+886287923100
Email
director@mail.ndmctsgh.edu.tw
First Name & Middle Initial & Last Name & Degree
Chin Lin, PhD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Artificial Intelligence-assisted Diagnosis and Prognostication in Low Ejection Fraction Using Electrocardiograms
We'll reach out to this number within 24 hrs